SCHEMBL26091653

SCHEMBL26091653

CSC1=N/C(=C\c2ccc3[nH]cnc3c2)C(=O)N1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.58
▸ GAA P10253 1/20 0.58
▸ DYRK3 O43781 8/20 0.56
▸ DYRK1A Q13627 8/20 0.56
▸ DYRK2 Q92630 8/20 0.56
▸ DYRK1B Q9Y463 8/20 0.56
▸ PIM1 P11309 5/20 0.56
▸ CSNK2A2 P19784 5/20 0.56
▸ CSNK2B P67870 5/20 0.56
▸ CSNK2A1 P68400 5/20 0.56
▸ CSNK2A3 Q8NEV1 5/20 0.56
▸ HPGD P15428 2/20 0.55
▸ KDM4E B2RXH2 3/20 0.48
▸ GPR18 Q14330 3/20 0.47
▸ CNR1 P21554 1/20 0.47
▸ CNR2 P34972 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.41
▸ CA2 P00918 2/20 0.37
▸ CLK1 P49759 4/20 0.36
▸ CLK2 P49760 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494355 1.00 MAPT (0.58) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL30494246 0.87 KDM4E (0.60) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL23510481 0.82 KDM4E (0.48) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL30363453 0.81 MAPT (0.62) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL24904266 0.78 KDM4E (0.60) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL30494162 0.76 MAPT (0.56) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL24904265 0.76 HDAC1 (0.43) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL23510557 0.75 DYRK1A (0.60) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL29899865 0.75 DYRK1A (0.60) MAPTGAADYRK3DYRK1ADYRK2
SCHEMBL28842985 0.75 DYRK1A (0.60) MAPTGAADYRK3DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 — — US disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
EP-4173675-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 CLK1, CLK2, CLK3 MAPT 312/4885GAA 3972/4885DYRK3 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback